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Abstract 
 
A retrospective audit of plasma HHV-8 viral load testing was performed in 
three HIV treatment centres over 24 months. Reasons for testing (360 tests) 
were: symptoms of systemic inflammatory response syndrome (fever, 
lymphadenopathy and raised inflammatory markers); monitoring in known 
HHV-8 pathology other than Kaposi sarcoma (KS); known/suspected KS, and 
other/no reason. Of patients with multicentric Castleman disease (MCD) 14/16 
(88%) had detectable plasma HHV-8, as did 27/45 (60%) with KS, and 6/19 
(32%) with lymphoma. Neither of the two patients with MCD and no 
detectable HHV-8 had SIRS symptoms at the time of the test. There was wide 
variation between centres in the indications prompting HHV-8 testing, with a 
more conservative approach resulting in a higher proportion of positive 
results. Measuring plasma HHV-8 in the absence of SIRS symptoms, 
established HHV-8 disease monitoring, or confirmed/suspected KS is unlikely 
to yield detectable HHV-8 thus allowing potential cost savings. 
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Introduction 
 
Human herpesvirus (HHV)-8-related diseases, including multicentric 
Castleman disease (MCD), Kaposi sarcoma (KS) and lymphoma cause 
significant morbidity in HIV-infected patients1.  HHV-8 can be detected by 
PCR in plasma of patients with HHV-8-related pathology2.  However, there is 
controversy regarding the clinical utility of plasma HHV-8 measurement in 
investigating patients with suspected HHV-8-related disease3,4 and a lack of 
guidance on indications for testing.   
 
Methods 
 
We performed a retrospective audit of plasma HHV-8 viral load testing across 
our network of three large UK HIV treatment centres from January 2012 to 
January 2013.  We reviewed case notes and laboratory results and recorded 
plasma HHV-8 DNA quantitation, indications for testing, patient 
demographics, antiretroviral therapy (ART) use and concurrent HIV viral load 
and CD4 measurements.  Confirmed HHV-8-related diagnoses were also 
recorded.  Case notes of patients with detectable HHV-8 and without an HHV-
8-related diagnosis were reviewed again 24 months after the audit period to 
ascertain if HHV-8-associated diagnoses had been made subsequently. 
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Results 
 
A total of 360 tests were requested across the three centres in the 24 month 
period. Reasons for testing were: symptoms of systemic inflammatory 
response syndrome (SIRS) such as fever, lymphadenopathy and raised 
inflammatory markers; monitoring in known HHV-8 pathology other than KS; 
investigation of known/suspected KS, and other/no reason (Figure 1a). 
 
Figure 1a: Number of plasma HHV-8 DNA viral load tests by indication 
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Plasma HHV-8 was detectable by PCR in 114/360 (31.7%) tests.  The 
proportion of samples with detectable HHV-8 according to the reason for the 
test is shown in Figure 1b. 
 
 
Figure 1b: Proportion of samples with detectable HHV-8 by indication 
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Patients with detectable HHV-8 were more likely to be male (94% vs 68%, 
p<0.002 two tailed Fisher exact test), MSM (48% vs 29%, p=0.016), be 
receiving ART (79% vs 64%, p=0.006) and to have an undetectable HIV viral 
load (59% vs 45%, p=0.0024).  Median CD4 cell count was 280 cells/mm3 in 
those with detectable HHV-8 compared with 285 cells/mm3 in those without.  
Of patients with MCD 14/16 (88%) had detectable plasma HHV-8, as did 
27/45 (60%) with biopsy proven or clinically confirmed KS, and 6/19 (32%) 
with lymphoma (primary effusion lymphoma (n=4) and plasmablastic 
lymphoma (n=2)). Neither of the two patients with MCD and no detectable 
HHV-8 had SIRS symptoms at the time of the test. 
 
Reasons for ordering plasma HHV-8 DNA quantitation varied between centres 
(Table 1).   
 
Table 1: HHV-8 viral load testing: indication and yield by study centre 
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Centre No Total number of 
HIV patients 
attending centre 
Reason for 
test 
Tests 
ordered 
Detectable 
HHV-8 
1 4200 SIRS 85 18 (21%) 
Monitoring 46 32 (70%) 
KS 15 6 (40%) 
Other 24 0 (0%) 
2 3203 SIRS 16 7 (44%) 
Monitoring 33 23 (69%) 
KS 0 - 
Other 8 1 (13%) 
3 1148 SIRS 57 10 (18%) 
Monitoring 17 14 (82%) 
KS 3 0 (0%) 
Other 56 3 (5%) 
 
 
Eighteen patients had detectable plasma HHV-8 DNA in the absence of any 
HHV-8-related diagnosis during the audit period of whom sixteen had SIRS 
symptoms which prompted the test and four had no clear indication recorded. 
Their case notes were reviewed again 24 months later.  Eleven patients had 
HHV-8 DNA levels of <10,000 copies/ml and had no subsequent HHV8-
related diagnosis. Two patients had levels of 30,920 and 22,000 copies/ml but 
with no subsequent relevant diagnoses or HHV-8 levels requested. One 
patient had a level of 43 copies/ml in the absence of SIRS symptoms, but 
MCD was subsequently diagnosed in the context of SIRS symptoms and an 
HHV-8 DNA level of 13,000 copies/ml.  Two patients with SIRS symptoms 
had very high plasma HHV-8 DNA levels (825,000 and 3,300,000 copies/ml) 
and died soon after the tests were sent.  One patient with SIRS symptoms 
and an HHV-8 DNA level of 167,100 copies/ml was later diagnosed MCD after 
two non-diagnostic biopsies. One patient, with newly diagnosed HIV infection, 
had SIRS symptoms and a plasma HHV-8 DNA level of 577,400 copies/ml, 
which became undetectable with ART. 
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Discussion 
 
There is wide variation between our centres in the indications prompting HHV-
8 testing, with a more conservative approach resulting in a higher proportion 
of positive results. The audit suggests that measuring plasma HHV-8 in the 
absence of SIRS symptoms, established HHV-8 disease monitoring or 
confirmed/suspected KS is unlikely to yield detectable HHV-8 thus allowing 
potential cost savings.  The higher likelihood of HHV-8 viraemic patients to be 
on suppressive ART is of interest given the well-documented phenomenon of 
MCD and HHV-8 viraemia as an immune reconstitution inflammatory 
syndome 5,6in contrast to KS which usually improves or resolves with ART7. 
 
We found a high prevalence of HHV-8 viraemia in patients with MCD. There 
were two confirmed MCD patients with undetectable plasma HHV-8 levels but 
neither had SIRS symptoms at the time of testing suggesting the MCD was in 
remission.  This implies that in patients presenting with SIRS symptoms, an 
undetectable plasma HHV-8 level makes active MCD unlikely in consistent 
with longitudinal cohort data8 and with conclusions from a recent evaluation of 
the use of the test as a tumour biomarker4.   
 
The detection of HHV-8 in plasma of patients without a confirmed HHV8-
related diagnosis can provoke uncertainty.  Our data suggest that low HHV8 
levelsin the absence of SIRS symptoms or known HHV-8 related disease are 
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unlikely to be of clinical significance.  Nonetheless, in view of the low plasma 
HHV8 levels seen in some HHV8-related conditions, notably KS3, these 
patients should be closely monitored for symptoms.  Conversely, persistent 
high levels of HHV-8 viraemia in a symptomatic patient, when tissue biopsy is 
non-diagnostic or unavailable should arouse suspicion of undiagnosed HHV-8 
related pathology and prompt further investigation.   
 
While histological diagnosis remains the gold standard for diagnosing 
MCD9,10, the condition is relapsing and remitting in nature and confirmation by 
tissue biopsy can be problematic.  The introduction of effective therapies for 
MCD, particularly rituximab, has dramatically improved survival and 
prognosis11, hence more attention is needed to determine whether to proceed 
with treatment in the absence of a histological diagnosis when clinical features 
suggestive of MCD are accompanied by a high plasma HHV-8 level.   
 
This audit adds to the current understanding of the relationship between HHV-
8 viraemia and disease and highlights the need for clinical guidance in the use 
of HHV-8 quantitation. 
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